Please use this identifier to cite or link to this item:
Title: Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis
Author: Shah, Nirav N.
Ahn, Kwang Woo
Litovich, Carlos
Fenske, Timothy S.
Ahmed, Sairah
Battiwalla, Minoo
Bejanyan, Nelli
Dahi, Parastoo B.
Bolaños Meade, Javier
Chen, Andy I.
Ciurea, Stefan O.
Bachanova, Veronika
DeFilipp, Zachariah
Epperla, Narendranath
Farhadfar, Nosha
Herrera, Alex F.
Haverkos, Bradley M.
Holmberg, Leona
Hossain, Nasheed M.
Kharfan-Dabaja, Mohamed A.
Kenkre, Vaishalee P.
Lazarus, Hillard M.
Murthy, Hemant S.
Nishihori, Taiga
Rezvani, Andrew R.
D'Souza, Anita
Savani, Bipin N.
Ulrickson, Matthew L.
Waller, Edmund K.
Sureda, Anna
Smith, Sonali M.
Hamadani, Mehdi
Keywords: Cèl·lules canceroses
Malaltia de Hodgkin
Cancer cells
Hodgkin's disease
Issue Date: 23-Apr-2018
Publisher: American Society of Hematology
Abstract: The application of allogeneic hematopoietic cell transplantation (allo-HCT) in non-Hodgkin lymphoma (NHL) patients ≥65 years in the United States is limited by lack of Medicare coverage for this indication. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we report allo-HCT outcomes of NHL patients aged ≥65 years (older cohort; n = 446) compared with a cohort of younger NHL patients aged 55-64 years (n = 1183). We identified 1629 NHL patients undergoing a first reduced-intensity conditioning (RIC) or nonmyeloablative conditioning allo-HCT from 2008 to 2015 in the United States. Cord blood or haploidentical transplants were excluded. The median age was 68 years (range 65-77) for the older cohort vs 60 years (range 55-64) in the younger cohort. The 4-year adjusted probabilities of nonrelapse mortality (NRM), relapse/progression (R/P), progression-free survival (PFS), and overall survival (OS) of the younger and older groups were 24% vs 30% (P = .03), 41% vs 42% (P = .82), 37% vs 31% (P = .03), and 51% vs 46% (P = .07), respectively. Using multivariate analysis, compared with the younger group, the older cohort was associated with increased NRM, but there was no difference between the 2 cohorts in terms of R/P, PFS, or OS. The most common cause of death was disease relapse in both groups. In NHL patients eligible for allo-HCT, there was no difference in OS between the 2 cohorts. Age alone should not determine allo-HCT eligibility in NHL, and Medicare should expand allo-HCT coverage to older adults.
Note: Reproducció del document publicat a:
It is part of: Blood Advances, 2018, vol. 2, num. 8, p. 933-940
Related resource:
ISSN: 2473-9529
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
696016.pdf947.17 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.